In contrast to the limited targeted strategies currently available for PCa, this EVs-mediated siRNA delivery system represents a precision therapeutic strategy that specifically silences HSPD1 in tumor cells, demonstrating favorable safety and efficacy profiles and offering a novel potential approach for targeted PCa therapy. This evidence concerns the gene HSPD1 and posterior cortical atrophy.